EN DE
Watch Vaxcell-Bio Therapeutics Co. Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Vaxcell-Bio Therapeutics Co. Ltd (323990) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Vaxcell-Bio Therapeutics Co. Ltd stock KRW 1,046, price KRW 3,720, that is 71.9% below the price, quality 31 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR

VB Vaxcell-Bio Therapeutics Co. Ltd logo Thin data Nov 9, 2026

Vaxcell-Bio Therapeutics Co. Ltd

323990 · KQ
Very expensive, weak quality

Our calculation puts a fair price 72% below what the stock costs today.

Low debt
Mixed Growth (revenue YoY +271.6 %/yr in KRW)
Fair value 1,046 KRW · Strongly overvalued
Quality 31/100
Loss-making · -189.1% net margin (FY2025)
Negative free cash flow
Trails peers (2/8)
Narrow moat 12/100
Thin data
Watch Vaxcell-Bio Therapeutics Co. Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

72,787 KRW 3,585 KRW Fair Value 1,046 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.

How to read this chart

60‑month range 3,585 KRW – 72,787 KRW · fair‑value band 690.13 KRW – 1,307 KRW · the 3,720 KRW price screens above the 1,046 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.

Follow Vaxcell-Bio Therapeutics Co. in your weekly email

Every Wednesday you see whether Vaxcell-Bio Therapeutics Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Vaxcell-Bio Therapeutics Co., Ltd. develops and anticancer immunotherapy products in South Korea. The company was founded in 2010 and is headquartered in Hwasun-eup, South Korea.

Stock analysis

Vaxcell-Bio Therapeutics Co. Ltd (323990) currently trades at 3,720 KRW, while our model-based Fair Value estimate is 1,046 KRW, 72% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.

Scenario range: 690.13 KRW (bear) to 1,307 KRW (bull), the price of 3,720 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 31/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Vaxcell-Bio Therapeutics Co. Ltd reported revenue of 7.1B KRW in FY2025 versus 0 KRW in FY2021. Reported net income was −13.3B KRW in FY2025.

Key figures

Market cap 86.2B KRW (≈ $63.7M) Micro · Return on equity −20.5% · Return on assets (EBIT) −21.8% (5-year average) · Operating margin −731% · Free cash flow −17.4B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 66% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −72%, 323990 screens richer than that median.

Fair Value models

Bear 690.13 KRW Fair Value 1,046 KRW Bull 1,307 KRW
Price 3,720 KRW · Downside -71.9%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) 690.13 KRW 1,046 KRW 1,307 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 690.13 KRW 1,046 KRW 1,307 KRW 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 31/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 58
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 81
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 14
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 34
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 23/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

323990 screens overvalued: fair value 72% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Vaxcell-Bio Therapeutics Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 558 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 31 · Bottom 25%
Fair Value upside −71.9% · Below median
Profitability
Return on assets −19.9% · Below median
Net margin (12 months) −189.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity 0.15× · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.41× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)93 · sector 97
DIVIDEND (yield)0 · sector 22

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Incyte Corporation INCY $119.65 $199.23 +67% vs 323990
Regeneron Pharmaceuticals, Inc REGN $904.35 $1,275 +41% vs 323990
Vertex Pharmaceuticals Incorporated VRTX $547.09 $601.80 +10% vs 323990
Samsung Biologics Co 207940 1,516,000 KRW 1,667,600 KRW +10% vs 323990
Genmab A/S GMAB kr 3,527 kr 3,880 +10% vs 323990
WuXi Biologics (Cayman) Inc 2269 HK$47.62 HK$52.38 +10% vs 323990
argenx SE ARGX $927.21 $908.40 −2% vs 323990
CSL Limited CSL A$200.77 A$183.04 −9% vs 323990
Celltrion, Inc 068270 211,000 KRW 74,945 KRW −64% vs 323990
Royalty Pharma plc RPRX $67.30 $19.01 −72% vs 323990

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Vaxcell-Bio Therapeutics Co. Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Vaxcell-Bio Therapeutics Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/323990

Frequently asked questions

Is Vaxcell-Bio Therapeutics Co. Ltd (323990) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 1,046 KRW versus a price of 3,720 KRW, about 72% lower (overvalued).
What is the fair value of 323990?
Our model-based fair value for Vaxcell-Bio Therapeutics Co. Ltd is 1,046 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 3,720 KRW.
What is the quality score of 323990?
Vaxcell-Bio Therapeutics Co. Ltd has a Quality Score of 31/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Vaxcell-Bio Therapeutics Co. Ltd (323990)?
Our model-based price target is the fair value of 1,046 KRW (as of Nov 9, 2026) from 1 valuation models. Cautious scenario 690.13 KRW, optimistic scenario 1,307 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Vaxcell-Bio Therapeutics Co. Ltd stock forecast for 2026?
Our models put fair value at 1,046 KRW, about 72% lower versus a price of 3,720 KRW (overvalued). Cautious scenario 690.13 KRW, optimistic scenario 1,307 KRW. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Vaxcell-Bio Therapeutics Co. Ltd (323990)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Vaxcell-Bio Therapeutics Co. Ltd it is 1,046 KRW per share (as of Nov 9, 2026), against a price of 3,720 KRW. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Vaxcell-Bio Therapeutics Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 323990 trades above its calculated fair value: price 3,720 KRW, fair value 1,046 KRW, a gap of about −72% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 323990?
No. The price is what the market pays today (3,720 KRW); the fair value is what the company's own numbers justify (1,046 KRW). For Vaxcell-Bio Therapeutics Co. Ltd the two are 2,674 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Vaxcell-Bio Therapeutics Co. Ltd worth?
The market values Vaxcell-Bio Therapeutics Co. Ltd at about 86.2B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 3,720 KRW; our models calculate a fair value of 1,046 KRW per share.
What do the bullish and bearish scenarios say about 323990?
Our models span a range for Vaxcell-Bio Therapeutics Co. Ltd: cautious scenario 690.13 KRW, base 1,046 KRW, optimistic 1,307 KRW per share (as of Nov 9, 2026, price 3,720 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Vaxcell-Bio Therapeutics Co. Ltd (323990)?
Balance-sheet figures for Vaxcell-Bio Therapeutics Co. Ltd (as of Nov 9, 2026): return on equity −20.5%, debt of 0.15 per unit of equity. They feed the Quality Score of 31/100, which measures business quality independently of the share price.
How far is 323990 from its 52-week high?
Vaxcell-Bio Therapeutics Co. Ltd trades at 3,720 KRW, about 66% below its 52-week high of 11,000 KRW and 4% above the low of 3,585 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 1,046 KRW is for.
Which stocks are comparable to Vaxcell-Bio Therapeutics Co. Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Vaxcell-Bio Therapeutics Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 3,720 KRW, calculated fair value 1,046 KRW (−72%), Quality Score 31/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 323990 calculated?
We run Vaxcell-Bio Therapeutics Co. Ltd through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of 1,046 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Vaxcell-Bio Therapeutics Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Vaxcell-Bio Therapeutics Co. Ltd (323990)?
The closing price on Nov 6, 2026 was 3,720 KRW. Our model-based fair value is 1,046 KRW, about 72% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Vaxcell-Bio Therapeutics Co. Ltd right now?
The price sits above even our optimistic bull case (1,307 KRW). The favourable scenario is already priced in. Weak quality (31/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (690.13 KRW to 1,307 KRW) leaves room in how you read the outcome.

Key figures of Vaxcell-Bio Therapeutics Co. Ltd

How large is the market capitalisation of Vaxcell-Bio Therapeutics Co. Ltd (323990)?
The market capitalisation of Vaxcell-Bio Therapeutics Co. Ltd is 86.2B KRW (≈ $63.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of Vaxcell-Bio Therapeutics Co. Ltd (323990)?
The return on equity (ROE) of Vaxcell-Bio Therapeutics Co. Ltd is −20.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Vaxcell-Bio Therapeutics Co. Ltd (323990)?
On an EBIT basis the return on assets of Vaxcell-Bio Therapeutics Co. Ltd is −21.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Vaxcell-Bio Therapeutics Co. Ltd (323990)?
The operating margin of Vaxcell-Bio Therapeutics Co. Ltd is −731% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Vaxcell-Bio Therapeutics Co. Ltd (323990) generate?
The free cash flow of Vaxcell-Bio Therapeutics Co. Ltd is −17.4B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Vaxcell-Bio Therapeutics Co. Ltd in the live analysis

One click puts Vaxcell-Bio Therapeutics Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.